|
1
|
Schoenfeld J, Jinushi M, Nakazaki Y, et
al: Active immunotherapy induces antibody responses that target
tumor angiogenesis. Cancer Res. 70:10150–10160. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Noori S, Taghikhani M, Hassan ZM, Allameha
A and Mostafaei A: Tehranolide molecule modulates the immune
response, reduce regulatory T cell and inhibits tumor growth in
vivo. Mol Immunol. 47:1579–1584. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lesterhuis WJ, Punt CJ, Hato SV, et al:
Platinum-based drugs disrupt STAT6-mediated suppression of immune
responses against cancer in humans and mice. J Clin Invest.
121:3100–3108. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wieder T, Braumüller H, Kneilling M,
Pichler B and Röcken M: T cell-mediated help against tumors. Cell
Cycle. 7:2974–2977. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Forte G, Sorrentino R, Montinaro A, et al:
Inhibition of CD73 improves B cell-mediated anti-tumor immunity in
a mouse model of melanoma. J Immunol. 189:2226–2233. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kandasamy M, Bay BH, Lee YK and Mahendran
R: Lactobacilli secreting a tumor antigen and IL15 activates
neutrophils and dendritic cells and generates cytotoxic T
lymphocytes against cancer cells. Cell Immunol. 271:89–96. 2011.
View Article : Google Scholar
|
|
7
|
Schwandt A, Garcia JA, Elson P, et al:
Clinical and immunomodulatory effects of celecoxib plus
interferon-alpha in metastatic renal cell carcinoma patients with
COX-2 tumor immunostaining. J Clin Immunol. 31:690–698. 2011.
View Article : Google Scholar
|
|
8
|
Yamamoto M, Kamigaki T, Yamashita K, et
al: Enhancement of anti-tumor immunity by high levels of Th1 and
Th17 with a combination of dendritic cell fusion hybrids and
regulatory T cell depletion in pancreatic cancer. Oncol Rep.
22:337–343. 2009.PubMed/NCBI
|
|
9
|
Kuper H, Adami HO and Trichopoulos D:
Infections as a major preventable cause of human cancer. J Intern
Med. 248:171–183. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mareel M and Madani I: Tumour-associated
host cells participating at invasion and metastasis: targets for
therapy? Acta Chir Belg. 106:635–640. 2006.PubMed/NCBI
|
|
11
|
de Visser KE and Coussens LM: The
inflammatory tumor micro-environment and its impact on cancer
development. Contrib Microbiol. 13:118–137. 2006.
|
|
12
|
Kenny PA and Bissell MJ: Tumour reversion:
correction of malignant behavior by microenvironmental cues. Int J
Cancer. 107:688–695. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Revoltella RP, Menicagli M and Campani D:
Granulocyte-macrophage colony-stimulating factor as an autocrine
survival-growth factor in human gliomas. Cytokine. 57:347–359.
2012. View Article : Google Scholar
|
|
14
|
Curran CS, Evans MD and Bertics PJ: GM-CSF
production by glioblastoma cells has a functional role in
eosinophil survival, activation, and growth factor production for
enhanced tumor cell proliferation. J Immunol. 187:1254–1263. 2011.
View Article : Google Scholar
|
|
15
|
Liao HH, Wang YC, Chen MC, et al:
Down-regulation of granulocyte-macrophage colony-stimulating factor
by 3C-like proteinase in transfected A549 human lung carcinoma
cells. BMC Immunol. 12:162011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Inoue H, Iga M, Nabeta H, et al:
Non-transmissible Sendai virus encoding granulocyte macrophage
colony-stimulating factor is a novel and potent vector system for
producing autologous tumor vaccines. Cancer Sci. 99:2315–2326.
2008. View Article : Google Scholar
|
|
17
|
Ashizawa T, Okada R, Suzuki Y, et al:
Study of interleukin-6 in the spread of colorectal cancer: the
diagnostic significance of IL-6. Acta Med Okayama. 60:325–330.
2006.PubMed/NCBI
|
|
18
|
Bao B, Ahmad A, Kong D, et al: Hypoxia
induced aggressiveness of prostate cancer cells is linked with
deregulated expression of VEGF, IL-6 and miRNAs that are attenuated
by CDF. PLoS One. 7:e437262012. View Article : Google Scholar
|
|
19
|
Sato T, Omura M, Saito J, Hirasawa A,
Kakuta Y, Wakabayashi Y and Nishikawa T: Neutrophilia associated
with anaplastic carcinoma of the thyroid: production of macrophage
colony-stimulating factor (M-CSF) and interleukin-6. Thyroid.
10:1113–1118. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Riesco A: Five-year cancer cure: relation
to total amount of peripheral lymphocytes and neutrophils. Cancer.
25:135–140. 1970.PubMed/NCBI
|
|
21
|
Atzpodien J, Royston P, Wandert T and
Reitz M: DGCIN - German Cooperative Renal Carcinoma
Chemo-Immunotherapy Trials Group: Metastatic renal carcinoma
comprehensive prognostic system. Br J Cancer. 88:348–353. 2003.
View Article : Google Scholar
|
|
22
|
Négrier S, Escudier B, Gomez F, et al:
Prognostic factors of survival and rapid progression in 782
patients with metastatic renal carcinomas treated by cytokines: a
report from the Groupe Français d'Immunothérapie. Ann Oncol.
13:1460–1468. 2002.
|
|
23
|
Donskov F and von der Maase H: Impact of
immune parameters on long-term survival in metastatic renal cell
carcinoma. J Clin Oncol. 24:1997–2005. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Schmidt H, Suciu S, Punt CJ, et al
American Joint Committee on Cancer Stage IV Melanoma; EORTC 18951:
Pretreatment levels of peripheral neutrophils and leukocytes as
independent predictors of overall survival in patients with
American Joint Committee on Cancer Stage IV Melanoma: results of
the EORTC 18951 Biochemotherapy Trial. J Clin Oncol. 25:1562–1569.
2007. View Article : Google Scholar
|
|
25
|
Liu H, Tabuchi T, Takemura A, et al: The
granulocyte/lymphocyte ratio as an independent predictor of tumour
growth, metastasis and progression. Mol Med Rep. 1:699–704.
2008.PubMed/NCBI
|
|
26
|
Ietomi K: A study on the role of
granulocytes in carcinoma-bearing hosts - G/L ratio as a new host
indicator. Nippon Gan Chiryo Gakkai Shi. 25:662–671. 1990.(In
Japanese).
|
|
27
|
Lee YS, Choi I, Ning Y, et al:
Interleukin-8 and its receptor CXCR2 in the tumour microenvironment
promote colon cancer growth, progression and metastasis. Br J
Cancer. 106:1833–1841. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jung MY, Kim SH, Cho D and Kim TS:
Analysis of the expression profiles of cytokines and
cytokine-related genes during the progression of breast cancer
growth in mice. Oncol Rep. 22:1141–1147. 2009.PubMed/NCBI
|
|
29
|
Balkwill F and Mantovani A: Inflammation
and cancer: back to Virchow? Lancet. 357:539–545. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Arenberg DA, Kunkel SL, Polverini PJ,
Glass M, Burdick MD and Strieter RM: Inhibition of interleukin-8
reduces tumori-genesis of human non-small cell lung cancer in SCID
mice. J Clin Invest. 97:2792–2802. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ferrara N and Davis-Smyth T: The biology
of vascular endothelial growth factor. Endocr Rev. 18:4–25. 1997.
View Article : Google Scholar
|
|
32
|
Mizukami Y, Jo WS, Duerr EM, et al:
Induction of interleukin-8 preserves the angiogenic response in
HIF-1alpha-deficient colon cancer cells. Nat Med. 11:992–997.
2005.PubMed/NCBI
|
